MIGENIX Reports Second Quarter Fiscal Year 2008 Financi...(/p Other projects 0....)

Other projects 0.0 0.1 0.0 0.1

--------------------------------------------

Total Program Expenses 0.4 0.9 0.8 1.3

--------------------------------------------

Unattributed Expenses

Personnel 0.8 0.7 1.5 1.3

Patent costs 0.3 0.2 0.6 0.3

Other 0.3 0.4 0.6 0.6

--------------------------------------------

Total Unattributed Expenses 1.4 1.3 2.7 2.2

--------------------------------------------

Total Research & Development

Expenses $1.8 $2.2 $3.5 $3.5

--------------------------------------------

--------------------------------------------

(1) Before amortization expense, technology and license acquisition

costs, and write-offs of intangibles assets.

(2) Value of $0.0 million represents $nil to ~$50,000 in expenses during

the period.

Our Omiganan programs are being advanced by development and commercialization partners (Cadence Pharmaceuticals and Cutanea Life Sciences).

Celgosivir program costs were $0.3 million in Q2/08 (Q2/07: $0.2 million) and were $0.7 million for YTD Fiscal 2008 (YTD Fiscal 2007: $0.6 million).

Costs in the MX-2401 program in Q2/08 were $0.1 million (Q2/07: $0.6 million) and were $0.1 million for YTD Fiscal 2008 (YTD Fiscal 2007: $0.6 million). The decrease in Q2/08 and YTD Fiscal 2008 MX-2401 costs is principally due to higher cost manufacturing activity in Q2/07 and YTD Fiscal 2007 in preparation for the GLP studies started in April 2007. The MX-240
'/>"/>